News

Medscape3m
FDA Approves First One-Time Topical Treatment for Recessive Dystrophic Epidermolysis Bullosa Wounds
In a phase 3 trial, 81% of wounds treated with autologous cell sheet-based gene therapy showed ≥ 50% healing at 6 months, ...
AZoSensors on MSN2h
Wristwatch-Sized Device Enables Real-Time Tracking of Circulating Cells
MIT's CircTrek enables real-time monitoring of circulating blood cells, providing critical data for timely medical ...
BioSpace3h
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
L'Oreal Cell BioPrint | Review
L'Oreal is one of Kate's favorite stops at CES every year, and at CES 2025, the beauty tech innovator brought a new ...